Get the Stockscreener App
0.671
0.42%
0.0013
Sangamo Therapeutics Inc stock is traded at $0.671, with a volume of 5.11M.
It is up +0.42% in the last 24 hours and up +33.71% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$0.6723
Open:
$0.6892
24h Volume:
5.11M
Relative Volume:
0.92
Market Cap:
$202.27M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-0.8947
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
-3.42%
1M Performance:
+33.71%
6M Performance:
-6.04%
1Y Performance:
-19.36%
1-Day Range:
$0.60
$0.70
1-Week Range:
$0.60
$0.7646
52-Week Range:
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.6704 | 202.84M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.43 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
802.13 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.64 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Combining price and volume data for Sangamo Therapeutics Inc.2025 Market Overview & Low Risk Growth Stock Ideas - newser.com
What machine learning models say about Sangamo Therapeutics Inc.Rate Cut & Reliable Breakout Forecasts - newser.com
Combining machine learning predictions for Sangamo Therapeutics Inc.Global Markets & Stock Timing and Entry Methods - newser.com
How Sangamo Therapeutics Inc. stock reacts to bond yields2025 Market WrapUp & Daily Profit Maximizing Trade Tips - newser.com
Multi factor analysis applied to Sangamo Therapeutics Inc.2025 Breakouts & Breakdowns & Safe Entry Zone Tips - newser.com
Published on: 2025-10-12 23:29:27 - newser.com
Is Sangamo Therapeutics Inc. (GBY) stock a fit for income portfolios2025 Short Interest & Accurate Buy Signal Notifications - newser.com
Will earnings trigger a reversal in Sangamo Therapeutics Inc.Entry Point & Free Verified High Yield Trade Plans - newser.com
Sangamo Therapeutics (NASDAQ:SGMO) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Volume spikes in Sangamo Therapeutics Inc. stock – what they meanWeekly Investment Summary & Community Consensus Stock Picks - newser.com
What analysts say about Sangamo Therapeutics Inc stockAnalyst Upgrades & Compound Your Gains With Quality Stocks - earlytimes.in
There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 28% Share Price Rise - simplywall.st
Visual trend scoring systems applied to Sangamo Therapeutics Inc.Weekly Profit Summary & Step-by-Step Swing Trade Plans - newser.com
Published on: 2025-10-06 03:38:37 - newser.com
Why Sangamo Therapeutics Inc. (GBY) stock stays on buy listsEarnings Miss & Weekly Breakout Stock Alerts - newser.com
Is Sangamo Therapeutics Inc. (GBY) stock a good hedge against inflationWeekly Market Outlook & Weekly High Return Stock Opportunities - newser.com
Published on: 2025-10-05 05:08:49 - newser.com
What hedge fund activity signals for Sangamo Therapeutics Inc. stock2025 Price Targets & High Return Stock Watch Alerts - newser.com
Published on: 2025-10-05 02:36:48 - newser.com
Published on: 2025-10-03 07:10:00 - newser.com
How to monitor Sangamo Therapeutics Inc. with trend dashboards2025 Performance Recap & Fast Entry High Yield Tips - newser.com
Why Sangamo Therapeutics Inc. (GBY) stock stays resilientEarnings Miss & Expert Verified Movement Alerts - newser.com
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Sangamo Biosciences CFO Resigns, New Officer Appointed - MSN
BRIEF-Sangamo Therapeutics Appoints Nikunj Jain As Principal Accounting Officer – SEC Filing - NewsX
Sangamo Therapeutics appoints Nikunj Jain as principal accounting officerSEC filing - MarketScreener
Sangamo Therapeutics, Inc. Appoints Nikunj Jain as Principal Accounting Officer, Effective October 1, 2025 - MarketScreener
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Price Is Right But Growth Is Lacking After Shares Rocket 28% - 富途牛牛
What analysts say about Tomra Systems ASA TMRA stockStochastic Oscillator Alerts & Target Triple-Digit Stock Opportunities - earlytimes.in
Published on: 2025-09-29 00:48:43 - newser.com
Published on: 2025-09-28 22:48:05 - newser.com
Can Olympia Industries Limited Maintain Its Share of Global Market for Its ProductBollinger Bands Signals & Exceptional Capital Growth - earlytimes.in
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):